GRANDPHARMA (00512.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec29

Farapulse Secures Commercialization Rights for Neffy® in Mainland China

09:07

Dec23

Farmito Obtains Exclusive Commercialization Rights for Neffy® in Mainland China

09:10

Dec21

Yongan Pharmaceutical's TLX591-CDx Phase III Clinical Trial Reaches Primary Endpoint

10:14

Dec19

19:14

Dec17

Fujian Grand Pharmaceutical's Radioactive Drug Approved by FDA for Clinical Trials

10:09

Dec15

Guoyuan International Upgrades Views on Far East Medical’s Innovative Drug R&D, Raises Target Price

09:22

Schedules & Filings

Schedules

Filings

Aug19

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 3.054 B, Net Income 584.51 M, EPS 0.1669

Apr28

Distribution Plan(CST)

Cash dividend 0.26 HKD

Apr15

Distribution Plan(CST)

Cash dividend 0.26 HKD

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More